Loading viewer...
conference
Format: PDF conference
Nektar Therapeutics presents its biopharmaceutical pipeline and growth strategy at the 2017 JP Morgan Healthcare Conference. The presentation outlines proprietary drug candidates including NKTR-181, NKTR-214, NKTR-358, and NKTR-262, with projected annual revenue of $375-450M by 2021, supported by integrated R&D and manufacturing capabilities.
investor_presentation
31 Pages
conference
44 Pages
U.S. Chemical Safety Board
NESR 2020 J.P. Morgan Energy Power Renewables Conference
conferenceconference
21 Pages
National Energy Services Reunited Corp.